Noticias GSK plc - GSK | Acciones New York Stock Exchange

Su centro para precios en tiempo real, ideas y debates en vivo

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD Two...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased...

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables...

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration...

Monksdream 2 meses hace

GSK up and down but mostly up

👍️0

Monksdream 9 meses hace

GSK new 52 week high

👍️0

Monksdream 10 meses hace

GSK new 52 week high

👍️0

Monksdream 10 meses hace

GSK new 52 week high

👍️ 1

1jas 1 año hace

has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.

👍️0

MrHankey 1 año hace

Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

"Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

https://www.fda.gov/media/170006/download

👍️0

Magnum7419 1 año hace

i am in 100@ 34.56 :)

👍️0

Magnum7419 1 año hace

GSK #1 pick!!

👍️0

jondoeuk 2 años hace

Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x

👍️0

BottomBounce 2 años hace

$GSK Total Debt is $22.11 Billion // $8.00 should be trading

👍️0

rosemountbomber 2 años hace

Anyone know how we will calculate our cost basis in Haleon?

👍️0

ruke 2 años hace

So, why shares aren't realy mooning in pre-market? Isn't that strange?

👍️0

jondoeuk 2 años hace

Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071

👍️0

jondoeuk 2 años hace

Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

👍️0

jondoeuk 3 años hace

The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses LYEL's Epi-R https://lyell.com/our-platforms

New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''

👍️0

jondoeuk 3 años hace

They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm

👍️0

jondoeuk 3 años hace

Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html

👍️0

jondoeuk 3 años hace

Some more info https://lyell.com/our-platforms

👍️0

stillness0007 4 años hace

GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.

👍️0

testing4covid 4 años hace

Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19

Great article on an upcoming testing technology:

https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte

👍️0

whytestocks 4 años hace

Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management. But some investors might ...

Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out

👍️0

jondoeuk 4 años hace

Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221

👍️0

jondoeuk 4 años hace

SITC

Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)

👍️0

jondoeuk 4 años hace

Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

Refs:
1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
3 https://www.nature.com/articles/srep14896
4 https://cancerres.aacrjournals.org/content/70/21/8368.long
5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6

👍️0

jondoeuk 4 años hace

Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

Refs:
1 https://www.nature.com/articles/leu2015247
2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
3 https://cancerres.aacrjournals.org/content/75/2/296.long
4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
5 https://www.nature.com/articles/s41586-019-1805-z

👍️0

jondoeuk 4 años hace

Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level

👍️0

jondoeuk 4 años hace

A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

Refs:
1 https://clinicaltrials.gov/ct2/show/NCT04526509
2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research

👍️0

MustBeTheTruth 4 años hace

Better Development Tools for a New Golden Era of Psychopharmacology

https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/

👍️0

T695 4 años hace

Calls might sky rocket tomorrow

BottomBounce 5 años hace

Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8

👍️0

BottomBounce 5 años hace

$GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines

👍️0

BottomBounce 5 años hace

Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
Collaboration

https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx

👍️0

BottomBounce 5 años hace

**** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html

👍️0

Nebuchadnezzar 5 años hace

GSK-especially now in current market turmoil $35 looks XTRA tasty

👍️0

BottomBounce 5 años hace

Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

The infection prevention rate for $GSK 76.5% for Engerix-B

👍️0

BottomBounce 5 años hace

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

👍️0

BottomBounce 5 años hace

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent

👍️0

BottomBounce 5 años hace

$GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent

👍️0

Robbinhood101 5 años hace

Watch this one go up with Tesaro approval.

👍️0

I Need Money 5 años hace

Certainly a great LONG term hold. ;)

👍️0

Don'tDrinkTheKoolAid 5 años hace

YIKES haha nice up tick with a great divvy.

👍️0

I Need Money 5 años hace

$41.99 now. :)

👍️0

Don'tDrinkTheKoolAid 6 años hace

Yep 39 now with 5% divvy I don't own it now :(!

👍️0

DewDiligence 6 años hace

GSK, PFE form consumer-health JV: #msg-145552190.

👍️0

Dhubbard5 6 años hace

I agree with your theory completely make total sense.

👍️0

debunker1 6 años hace

Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

👍️0

Don'tDrinkTheKoolAid 7 años hace

Buy anything below 36 not much down side risk.

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

GSK plc (GSK)

Su centro para precios en tiempo real, ideas y debates en vivo

GSK Noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

GSK plc (GSK) Noticias

GSK plc (GSK)

Su centro para precios en tiempo real, ideas y debates en vivo

GSK Noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación